Eli Lilly to allow more patients to apply for special access to unapproved obesity drug
10 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Eli Lilly to allow more patients to apply for special access to unapproved obesity drug" is generating significant coverage in the Business category, with 11 articles from 10 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Houston Chronicle, MDLinx, STAT and RAPS. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 94d ago.
Quick answers
Why is "Eli Lilly to allow more patients to apply for special access to unapproved obesi" trending?
Because 10 independent news sources published 11 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (11)
- Eli Lilly will offer experimental obesity drug early to some patients. Who qualifies? Houston Chronicle · 97d ago
- Retatrutide access expands, putting physicians on the front line of ‘next-gen’ GLP-1 demand MDLinx · 97d ago
- Pharmalittle: We’re reading about a Lilly access program, a Gilead court victory, and more STAT · 97d ago
- Recon: Lilly to broaden expanded access for unapproved obesity drug; Jazz to withdraw second-line SCLC indication for Zepzelca RAPS · 97d ago
- Eli Lilly expanding early access to retatrutide weight loss drug qz.com · 97d ago
- Three biotechs with three news updates statnews.com · 97d ago
- This Next-Gen GLP-1 Is Blowing Up the Black Market Economy Marie Claire · 97d ago
- Retta Weight Loss: The Evidence, Benefits, and Realistic Expectations FC Bayern · 97d ago
- Spotlight On: Good news and bad news for Lilly's triple agonist FirstWord Pharma · 97d ago
- Eli Lilly to offer early access to next-gen obesity drug to some patients reuters.com · 97d ago
- Eli Lilly to allow more patients to apply for special access to unapproved obesity drug STAT · 97d ago
Topics
Related trends
Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data
Foghorn Therapeutics cuts 40% of staff after Eli Lilly ends a cancer collaboration due to poor data.
GLP-1 makers Novo, Eli Lilly sued over sudden loss of vision in patients
Major drugmakers Novo Nordisk and Eli Lilly face numerous lawsuits alleging popular GLP-1 medications cause sudden vision loss.
Did Texas get all the calls against Missouri? Eli Drinkwitz declines to blame refs for loss
3 news sources are covering this Sports story right now — PULSE is tracking how fast it spreads.
Eli Lilly Stock Jumps on Monster Earnings as Finance Chief Eyes Next Growth Engine
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly CFO On Acquisition Spree: 'We Are Taking Bets' On Future Revenue
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
Eli Lilly stock reaches an all-time high amid surging GLP-1 sales and a heightened price target.